Treatment landscape of triple-negative breast cancer—expanded options, evolving needs
Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
The lingering mysteries of metastatic recurrence in breast cancer
Despite being the hallmark of cancer that is responsible for the highest number of deaths,
very little is known about the biology of metastasis. Metastatic disease typically manifests …
very little is known about the biology of metastasis. Metastatic disease typically manifests …
Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment
AC Garrido-Castro, NU Lin, K Polyak - Cancer discovery, 2019 - AACR
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …
to treat. To date, therapies directed to specific molecular targets have rarely achieved …
Mechanisms of chemotherapy resistance in triple-negative breast cancer—how we can rise to the challenge
M Nedeljković, A Damjanović - Cells, 2019 - mdpi.com
Triple-negative (TNBC) is the most lethal subtype of breast cancer owing to high
heterogeneity, aggressive nature, and lack of treatment options. Chemotherapy remains the …
heterogeneity, aggressive nature, and lack of treatment options. Chemotherapy remains the …
Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies
YZ Jiang, D Ma, C Suo, J Shi, M Xue, X Hu, Y **ao… - Cancer cell, 2019 - cell.com
We comprehensively analyzed clinical, genomic, and transcriptomic data of a cohort of 465
primary triple-negative breast cancer (TNBC). PIK3CA mutations and copy-number gains of …
primary triple-negative breast cancer (TNBC). PIK3CA mutations and copy-number gains of …
The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer
L Ding, J Cao, W Lin, H Chen, X **ong, H Ao… - International journal of …, 2020 - mdpi.com
Cyclin-dependent kinases (CDKs) are serine/threonine kinases whose catalytic activities are
regulated by interactions with cyclins and CDK inhibitors (CKIs). CDKs are key regulatory …
regulated by interactions with cyclins and CDK inhibitors (CKIs). CDKs are key regulatory …
Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences
CL Braal, EM Jongbloed, SM Wilting, RHJ Mathijssen… - Drugs, 2021 - Springer
The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …
Molecular classification of breast cancer
JYS Tsang, MT Gary - Advances in anatomic pathology, 2020 - journals.lww.com
Cancer classification aims to provide an accurate diagnosis of the disease and prediction of
tumor behavior to facilitate oncologic decision making. Traditional breast cancer …
tumor behavior to facilitate oncologic decision making. Traditional breast cancer …
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers
characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs …
characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs …
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
A Marra, D Trapani, G Viale, C Criscitiello… - NPJ breast …, 2020 - nature.com
Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …